
|Videos|November 12, 2021
Bausch + Lomb: Update on FDA approval of XIPERE for macular edema associated with uveitis
Author(s)David Hutton, Alex Delaney-Gesing 
Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.
Advertisement
Ophthalmology Times'® David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest 
XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
 
 































